BMRA
Biomerica, Inc.2.3700
-0.0800-3.27%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
6.99MP/E (TTM)
-Basic EPS (TTM)
-1.53Dividend Yield
0%Recent Filings
10-Q
Q2 FY2026 results
Biomerica's Q2 FY2026 sales fell 26% y/y to $1.21M ended November 30, 2025, while gross profit plunged to $51K from $437K as cost of sales hit 96% of revenue; yet six-month sales dropped a milder 25% y/y to $2.59M with gross margin edging up to 18%. Operating loss widened 38% y/y to $1.37M on higher SG&A from sales hires and credit losses, offset by 25% lower R&D. Cash holds at $2.54M after $1.40M ATM equity raise, but ops burned $1.26M with no capex for FCF. Diluted EPS -$0.45 tracks 2.91M shares. Key customers dominate 55% sales. Customer concentration risks persist.
8-K
Annual meeting approves key amendments
Biomerica stockholders at the December 12, 2025 annual meeting elected five directors, including Zackary Irani and Gary Huff. They ratified Haskell & White as auditors, approved executive pay advisory, and amended the 2024 Stock Incentive Plan by 200,000 shares. Crucially, they boosted authorized common stock to 300 million shares. Flexibility secured.
10-Q
Q1 FY2026 results
Biomerica's Q1 FY2026 revenue fell 24% y/y to $1.38M, driven by softer clinical lab and contract manufacturing demand, yet gross profit climbed 47% to $424K on a 15-point margin expansion to 30.7% from efficiency gains and lower labor costs post-reduction in force. Operating loss narrowed 18% y/y to $1.12M, aided by 29% cuts in R&D spending, while a one-time $1.1M Employee Retention Credit refund flipped net results to a $2K profit—versus a $1.32M loss last year—yielding $0.00 diluted EPS on 2.64M shares. Cash swelled 27% q/q to $3.05M after $920K from ATM stock sales, though operations burned $268K; no debt burdens the balance sheet. One customer took 48% of sales. Going concern doubts linger amid funding needs. Competition from bigger players with deeper pockets remains a key risk.
8-K
Biomerica appoints diagnostics veteran
Biomerica expanded its board to six members on October 7, 2025, appointing Gary Huff, former CEO of LabCorp Diagnostics, as an independent director with over 35 years in laboratory testing and diagnostics. He joins the Audit, Compensation, and Nominating Committees, earning an annualized $45,000 cash fee, while Dr. Jane Emerson opted not to seek re-election at the December 12, 2025 annual meeting, shrinking the board back to five. Huff's expertise bolsters strategic growth in innovative products like inFoods IBS, which showed 59.6% abdominal pain reduction in a June 2025 study. This adds seasoned leadership amid expansion efforts.
10-K
FY2025 results
Biomerica's FY2025 revenue dipped 2% to $5.3 million from $5.4 million in FY2024, with over-the-counter sales plunging 26% amid tariff pressures, yet contract manufacturing surged 44% to $1.1 million, buoyed by inFoods IBS demand. Gross margins narrowed to 91% from 89% as higher inFoods costs offset labor savings, while operating expenses plunged 20% to $5.6 million via a 15% workforce cut and slashed R&D. Cash burned $3.8 million in operations, ending at $2.4 million after netting $2.0 million from ATM equity sales; backlog doubled to $1.3 million, mostly Asia-bound. No dividends or buybacks; capex stayed minimal at $37,000 for patents. Q4 momentum flickered with IBS physician uptake, but going concern doubts linger. Reliance on a single distributor for 31% of sales risks quarterly volatility.
ABT
Abbott Laboratories
126.86-1.61
BBNX
Beta Bionics, Inc.
29.63-0.09
BIO
Bio-Rad Laboratories, Inc.
302.02-5.90
BJDX
Bluejay Diagnostics, Inc.
0.97-0.04
BRKR
Bruker Corporation
44.96-0.71
CODX
Co-Diagnostics, Inc.
0.25-0.02
INBS
Intelligent Bio Solutions Inc.
5.50+0.00
LUCD
Lucid Diagnostics Inc.
1.12+0.01
OSUR
OraSure Technologies, Inc.
2.42-0.08
ZOMDF
Zomedica Corp.
0.11+0.00